PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES

(19)

(11)

EP 1 228 071 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	29.02.2012 Bulletin 2012/09

(45)	Mention of the grant of the patent:
	28.03.2007 Bulletin 2007/13

(21)	Application number: 00977095.9

(22)	Date of filing: 09.11.2000

(51)

International Patent Classification (IPC):

A61K 31/4035^(2006.01)
C07D 209/48^(2006.01)
C07D 403/06^(2006.01)
A61P 29/00^(2006.01)
A61P 35/02^(2006.01)

C07D 209/46^(2006.01)
C07D 403/04^(2006.01)
A61P 11/06^(2006.01)
A61P 35/00^(2006.01)
A61P 37/06^(2006.01)

(86)	International application number:
	PCT/US2000/030770

(87)	International publication number:
	WO 2001/034606 (17.05.2001 Gazette 2001/20)

(54)	PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES PHARMAZEUTISCH-AKTIVE ISOINDOLIN-DERIVATE DERIVES D'ISOINDOLINE ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

12.11.1999 US 165168 P
08.06.2000 US 590344
08.11.2000 US 708199

(43)	Date of publication of application:
	07.08.2002 Bulletin 2002/32

(60)	Divisional application:
	06009632.8 / 1698334
	10176390.2 / 2255801
	10176420.7 / 2263669

(73)	Proprietor: CELGENE CORPORATION
	Summit, NJ 07901 (US)

(72)	Inventors:
	MAN, Hon-Wah Neshanic Station, NJ 08853 (US) MULLER, George Rancho Santa Fe CA92067 (US)

(74)	Representative: Lawrence, John et al
	Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ Edgbaston Birmingham B16 8QQ (GB)

(56)

References cited: :

WO-A-00/25777
WO-A-96/20926
WO-A-97/23457
WO-A-99/06041

WO-A-95/01348
WO-A-97/08143
WO-A-98/24763

GIEMBYCZ M.A.: 'Phosphodiesterase 4 inhibitors and the treatment of asthma' DRUGS vol. 59, no. 2, February 2000, pages 193 - 212, XP002938449
MULLER G.W. ET AL.: 'Thalidomide analogs and PDE4 inhibition' BIOORG. MED. CHEM. LET. vol. 8, 1998, pages 2669 - 2674, XP002938448
DUPLANTIER A.J. ET AL.: '7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo(3,4-c )pyridines as novel inhibitors of human eosinophil phosphodiesterase' vol. 41, no. 13, May 1998, pages 2268 - 2277, XP002938447
MULLER G.W. ET AL.: 'Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity' J. MED. CHEM. vol. 39, 1996, pages 3238 - 3240, XP002938446
HE W. ET AL.: 'Novel cyclic compounds as potent phosphodiesterase 4 inhibitors' J. MED. CHEM. vol. 41, no. 22, October 1998, pages 4216 - 4223, XP002938445

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).